Small intestinal bacterial overgrowth – current, novel and possible future methods of treatment and diagnosis
DOI:
https://doi.org/10.56782/pps.196Keywords:
SIBO, Irritable Bowel Syndrome, Rifaximin, probiotics, Intestinal MicrobiotaAbstract
Small intestinal bacterial overgrowth (SIBO) is a prevalent issue, frequently overlooked in clinical practice. Its prevalence is unknown because SIBO requires diagnostic testing, however, in most studies, SIBO has been detected anywhere from <2% to 22% of healthy controls. Breath tests, which detect the presence of hydrogen in exhaled air, are the most used diagnostic method. However, their low sensitivity and specificity indicate the need for research into new more accurate methods. The standard treatment is antibiotic therapy with rifaximin. After antibiotic therapy, there is a risk of recurrence and the emergence of multidrug-resistant bacterial strains. Recurrence ratio after antibiotic therapy have been documented in 12.6% of patients after 3 months, 27.5% after 6 months and 43.7% after 9 months. There are promising results from studies on the use of probiotics and herbal preparations in treatment, but these studies have been conducted on relatively small groups of patients. This indicates the need for multicentre randomised trials with large numbers of patients to develop effective methods for the diagnosis and treatment of SIBO.
Downloads
References
Grace, E.; Shaw, C.; Whelan, K.; Andreyev, H.J.N. Review article: small intestinal bacterial overgrowth – prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment. Pharmacol. Ther. 2013, 38, 674–688. DOI: 10.1111/APT.12456 DOI: https://doi.org/10.1111/apt.12456
Skrzydło-Radomańska, B.; Cukrowska, B. How to Recognize and Treat Small Intestinal Bacterial Overgrowth? J. Clin. Med. 2022, 11(20), 6017. DOI: 10.3390/JCM11206017 DOI: https://doi.org/10.3390/jcm11206017
Krajicek, E.J.; Hansel, S.L. Small Intestinal Bacterial Overgrowth: A Primary Care Review. Mayo Clin. Proc. 2016, 91, 1828–1833. DOI: 10.1016/J.MAYOCP.2016.07.025 DOI: https://doi.org/10.1016/j.mayocp.2016.07.025
Rao, S.S.C.; Bhagatwala, J. Small Intestinal Bacterial Overgrowth: Clinical Features and Therapeutic Management. Clin. Trans. Gastroenterol. 2019, 10, e00078. DOI: 10.14309/CTG.0000000000000078 DOI: https://doi.org/10.14309/ctg.0000000000000078
Jacobs, C.; Coss Adame, E.; Attaluri, A.; Valestin, J.; Rao, S.S.C. Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth. Aliment. Pharmacol. Ther. 2013, 37, 1103–1111. DOI: 10.1111/apt.12304 DOI: https://doi.org/10.1111/apt.12304
Efremova, I.; Maslennikov, R.; Poluektova, E.; Vasilieva, E.; Zharikov, Y.; et al. Epidemiology of small intestinal bacterial overgrowth. World J. Gastroenterol. 2023, 29, 3400-3421. DOI: 10.3748/WJG.V29.I22.3400 DOI: https://doi.org/10.3748/wjg.v29.i22.3400
Gudan, A.; Jamioł-Milc, D.; Hawryłkowicz, V.; Skonieczna-Żydecka, K.; Stachowska, E. The Prevalence of Small Intestinal Bacterial Overgrowth in Patients with Non-Alcoholic Liver Diseases: NAFLD, NASH, Fibrosis, Cirrhosis-A Systematic Review, Meta-Analysis and Meta-Regression. Nutrients 2022, 14(24), Art. No: 5261. DOI: 10.3390/NU14245261 DOI: https://doi.org/10.3390/nu14245261
Rao, S.S.C.; Tan, G.; Abdulla, H.; Yu, S.; Larion, S.; et al. Does colectomy predispose to small intestinal bacterial (SIBO) and fungal overgrowth (SIFO)? Clin. Transl. Gastroenterol. 2018, 9, Art. No: 146. DOI: 10.1038/S41424-018-0011-X DOI: https://doi.org/10.1038/s41424-018-0011-x
Tansel, A.; Levinthal, D.J. Understanding Our Tests: Hydrogen-Methane Breath Testing to Diagnose Small Intestinal Bacterial Overgrowth. Clin. Transl. Gastroenterol. 2023, 14, Art. No: e00567. DOI: 10.14309/CTG.0000000000000567 DOI: https://doi.org/10.14309/ctg.0000000000000567
Gatta, L.; Scarpignato, C.; McCallum, R.W.; Lombardo, L.; Pimentel, M.; et al. Systematic review with meta‐analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment. Pharmacol. Ther. 2017, 45, 604-616. DOI: 10.1111/APT.13928 DOI: https://doi.org/10.1111/apt.13928
Franco, D.L.; Disbrow, M.B.; Kahn, A.; Koepke, L.M.; Harris, L.A.; et al. Duodenal Aspirates for Small Intestine Bacterial Overgrowth: Yield, PPIs, and Outcomes after Treatment at a Tertiary Academic Medical Center. Gastroenterol. Res. Pract. 2015, 2015, Art. ID: 971582. DOI: 10.1155/2015/971582 DOI: https://doi.org/10.1155/2015/971582
Guo, H.; Lu, S.; Zhang, J.; Chen, C.; Du, Y.; et al. Berberine and rifaximin effects on small intestinal bacterial overgrowth: Study protocol for an investigator-initiated, double-arm, open-label, randomized clinical trial (BRIEF-SIBO study). Front. Pharmacol. 2023, 14, Art. No: 1121435. DOI: 10.3389/FPHAR.2023.1121435/FULL DOI: https://doi.org/10.3389/fphar.2023.1121435
Achufusi, T.G.O.; Sharma, A.; Zamora, E.A.; Manocha, D. Small Intestinal Bacterial Overgrowth: Comprehensive Review of Diagnosis, Prevention, and Treatment Methods. Cureus 2020, 12(6), Art. No: e8860. DOI: 10.7759/CUREUS.8860 DOI: https://doi.org/10.7759/cureus.8860
Wang, Z.; Li, F.; Liu, J.; Luo, Y.; Guo, H.; et al. Intestinal Microbiota - An Unmissable Bridge to Severe Acute Pancreatitis-Associated Acute Lung Injury. Front. Immunol. 2022, 13, Art. No: 913178. DOI: 10.3389/FIMMU.2022.913178 DOI: https://doi.org/10.3389/fimmu.2022.913178
Dong, L.N.; Wang, M.; Guo, J.; Wang, J.P. Role of intestinal microbiota and metabolites in inflammatory bowel disease. Chin. Med. J. 2019, 132, 1610-1614. DOI: 10.1097/CM9.0000000000000290 DOI: https://doi.org/10.1097/CM9.0000000000000290
Rezaie, A.; Buresi, M.; Lembo, A.; Lin, H.; McCallum, R.; et al. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. Am. J. Gastroenterol. 2017, 112, 775–784. DOI: 10.1038/AJG.2017.46 DOI: https://doi.org/10.1038/ajg.2017.46
Paterson, W.; Camilleri, M.; Simren, M.; Boeckxstaens, G.; Vanner, S.J. Breath Testing Consensus Guidelines for SIBO: RES IPSA LOCQUITOR. Am. J. Gastroenterol. 2017, 112, 1888–1889. DOI: 10.1038/AJG.2017.233 DOI: https://doi.org/10.1038/ajg.2017.233
Pimentel, M.; Saad, R.J.; Long, M.D.; Rao, S.S.C. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Am. J. Gastroenterol. 2020, 115, 165–178. DOI: 10.14309/AJG.0000000000000501 DOI: https://doi.org/10.14309/ajg.0000000000000501
Smith, N.W.; Shorten, P.R.; Altermann, E.H.; Roy, N.C.; McNabb, W.C. Hydrogen cross-feeders of the human gastrointestinal tract. Gut Microbes 2019, 10, 270-288. DOI: 10.1080/19490976.2018.1546522 DOI: https://doi.org/10.1080/19490976.2018.1546522
Khoshini, R.; Dai, S.C.; Lezcano, S.; Pimentel, M. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig. Dis. Sci. 2008, 53, 1443–1454. DOI: 10.1007/S10620-007-0065-1/METRICS DOI: https://doi.org/10.1007/s10620-007-0065-1
Erdogan, A.; Rao, S.S.C.; Gulley, D.; Jacobs, C.; Lee, Y.Y.; et al. Small intestinal bacterial overgrowth: duodenal aspiration vs glucose breath test. Neurogastroenterol. Motil. 2015, 27, 481–489. DOI: 10.1111/NMO.12516 DOI: https://doi.org/10.1111/nmo.12516
Kalantar-Zadeh, K.; Berean, K.J.; Ha, N.; Chrimes, A.F.; Xu, K.; et al. A human pilot trial of ingestible electronic capsules capable of sensing different gases in the gut. Nat. Electron. 2018, 1, 79–87. DOI: 10.1038/s41928-017-0004-x DOI: https://doi.org/10.1038/s41928-017-0004-x
Singh, S.; Allan, N.; Wahl, C.; Lee, S.N.; Chuang, E.; et al. Sa1717 – Development of a Swallowable Diganostic Capsule to Monitor Gastrointestinal Health. Gastroenterology 2019, 156, Art. No: S-376. DOI: 10.1016/S0016-5085(19)37784-4 DOI: https://doi.org/10.1016/S0016-5085(19)37784-4
Nickles, M.A.; Hasan, A.; Shakhbazova, A.; Wright, S.; Chambers, C.J.; et al. Alternative Treatment Approaches to Small Intestinal Bacterial Overgrowth: A Systematic Review. J. Altern. Complement. Med. 2021, 27, 108–119. DOI: 10.1089/ACM.2020.0275 DOI: https://doi.org/10.1089/acm.2020.0275
Ginnebaugh, B.; Chey, W.D.; Saad, R. Small Intestinal Bacterial Overgrowth: How to Diagnose and Treat (and Then Treat Again). Gastroenterol Clin North Am. 2020, 49, 571–587. DOI: 10.1016/J.GTC.2020.04.010 DOI: https://doi.org/10.1016/j.gtc.2020.04.010
Quigley, E.M.M.; Murray, J.A.; Pimentel, M. AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review. Gastroenterology 2020, 159, 1526–1532. DOI: 10.1053/J.GASTRO.2020.06.090 DOI: https://doi.org/10.1053/j.gastro.2020.06.090
Lauritano, E.C.; Gabrielli, M.; Scarpellini, E.; Lupascu, A.; Novi, M.; et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am. J. Gastroenterol. 2008, 103, 2031–2035. DOI: 10.1111/J.1572-0241.2008.02030.X DOI: https://doi.org/10.1111/j.1572-0241.2008.02030.x
Shimura, S.; Ishimura, N.; Mikami, H.; Okimoto, E.; Uno, G.; et al. Small Intestinal Bacterial Overgrowth in Patients with Refractory Functional Gastrointestinal Disorders. J. Neurogastroenterol. Motil. 2016, 22, 60-68. DOI: 10.5056/JNM15116 DOI: https://doi.org/10.5056/jnm15116
Pimentel, M. Review of rifaximin as treatment for SIBO and IBS. Expert Opin. Investig. Drugs 2009, 18, 349–358. DOI: 10.1517/13543780902780175 DOI: https://doi.org/10.1517/13543780902780175
Wang, J.; Zhang, L.; Hou, X. Efficacy of rifaximin in treating with small intestine bacterial overgrowth: a systematic review and meta-analysis. Expert Rev. Gastroenterol. Hepatol. 2021, 15, 1385–1399. DOI: 10.1080/17474124.2021.2005579 DOI: https://doi.org/10.1080/17474124.2021.2005579
Ponziani, F.R.; Zocco, M.A.; D’Aversa, F.; Pompili, M.; Gasbarrini, A. Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation. World J. Gastroenterol. 2017, 23, 4491-4499. DOI: 10.3748/WJG.V23.I25.4491 DOI: https://doi.org/10.3748/wjg.v23.i25.4491
Kim, S.K.; Guevarra, R.B.; Kim, Y.T.; Kwon, J.; Kim, H.; et al. Role of Probiotics in Human Gut Microbiome-Associated Diseases. J. Microbiol. Biotechnol. 2019, 29, 1335–1340. DOI: 10.4014/JMB.1906.06064 DOI: https://doi.org/10.4014/jmb.1906.06064
Monteagudo-Mera, A.; Rastall, R.A.; Gibson, G.R.; Charalampopoulos, D.; Chatzifragkou, A. Adhesion mechanisms mediated by probiotics and prebiotics and their potential impact on human health. Appl. Microbiol. Biotechnol. 2019, 103, 6463–6472. DOI: 10.1007/S00253-019-09978-7 DOI: https://doi.org/10.1007/s00253-019-09978-7
Skrzydło-Radomańska, B.; Prozorow-Król, B.; Kurzeja-Mirosław, A.; Cichoż-Lach, H.; Laskowska, K.; et al. The Efficacy and Safety of Single-Strain Probiotic Formulations Containing Bifidobacterium lactis or Bacillus coagulans in Adult Patients with Irritable Bowel Syndrome—A Randomized Double-Blind Placebo-Controlled Three-Arm Interventional Trial. J. Clin. Med. 2023, 12, Art. No: 4838. DOI: 10.3390/JCM12144838 DOI: https://doi.org/10.3390/jcm12144838
Zhong, C.; Qu, C.; Wang, B.; Liang, S.; Zeng, B. Probiotics for Preventing and Treating Small Intestinal Bacterial Overgrowth: A Meta-Analysis and Systematic Review of Current Evidence. J. Clin. Gastroenterol. 2017, 51, 300–311. DOI: 10.1097/MCG.0000000000000814 DOI: https://doi.org/10.1097/MCG.0000000000000814
Rao, S.S.C.; Rehman, A.; Yu, S.; Andino, N.M. Brain fogginess, gas and bloating: a link between SIBO, probiotics and metabolic acidosis. Clin. Transl. Gastroenterol. 2018, 9(6), Art. No: 162. DOI: 10.1038/s41424-018-0030-7 DOI: https://doi.org/10.1038/s41424-018-0030-7
Wang, J.W.; Kuo, C.H.; Kuo, F.C.; Wang, Y.K.; Hsu, W.H.; et al. Fecal microbiota transplantation: Review and update. J. Formos. Med. Assoc. 2019, 118, 23–31. DOI: 10.1016/J.JFMA.2018.08.011 DOI: https://doi.org/10.1016/j.jfma.2018.08.011
Gupta, K.; Tappiti, M.; Nazir, A.M.; Koganti, B.; Memon, M.S.; et al. Fecal Microbiota Transplant in Recurrent Clostridium Difficile Infections: A Systematic Review. Cureus 2022, 14(5), Art. No: e24754. DOI: 10.7759/CUREUS.24754 DOI: https://doi.org/10.7759/cureus.24754
Chang, B.W.; Rezaie, A. Irritable Bowel Syndrome-Like Symptoms Following Fecal Microbiota Transplantation: A Possible Donor-Dependent Complication. Am. J. Gastroenterol. 2017, 112, 186–187. DOI: 10.1038/AJG.2016.472 DOI: https://doi.org/10.1038/ajg.2016.472
Allegretti, J.R.; Kassam, Z.; Chan, W.W. Small Intestinal Bacterial Overgrowth: Should Screening Be Included in the Pre-fecal Microbiota Transplantation Evaluation? Digest. Dis. Sci. 2018, 63, 193–197. DOI: 10.1007/S10620-017-4864-8/METRICS DOI: https://doi.org/10.1007/s10620-017-4864-8
Important Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Reactions Due to Transmission of Multi-Drug Resistant Organisms | FDA. 2019. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/important-safety-alert-regarding-use-fecal-microbiota-transplantation-and-risk-serious-adverse (Accessed 21 Jan 2024)
Dionne, J.; Ford, A.C.; Yuan, Y.; Chey, W.D.; Lacy, B.E.; et al. A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome. Am. J. Gastroenterol. 2018, 113, 1290–1300. DOI: 10.1038/S41395-018-0195-4 DOI: https://doi.org/10.1038/s41395-018-0195-4
Pimentel, M.; Constantino, T.; Kong, Y.; Bajwa, M.; Rezaei, A.; et al. A 14-day elemental diet is highly effective in normalizing the lactulose breath test. Digest. Dis. Sci. 2004, 49, 73–77. DOI: 10.1023/B:DDAS.0000011605.43979.E1 DOI: https://doi.org/10.1023/B:DDAS.0000011605.43979.e1
Wielgosz-Grochowska, J.P.; Domanski, N.; Drywień, M.E. Efficacy of an Irritable Bowel Syndrome Diet in the Treatment of Small Intestinal Bacterial Overgrowth: A Narrative Review. Nutrients 2022, 14(16), Art. No: 3382. DOI: 10.3390/NU14163382 DOI: https://doi.org/10.3390/nu14163382
Ghosh, G.; Jesudian, A.B. Small Intestinal Bacterial Overgrowth in Patients with Cirrhosis. J. Clin. Exp. Hepatol. 2019, 9, 257–267. DOI: 10.1016/J.JCEH.2018.08.006 DOI: https://doi.org/10.1016/j.jceh.2018.08.006
Madrid, A.M.; Hurtado, C.; Venegas, M.; Cumsille, F.; Defilippi, C. Long-Term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function. Am. J. Gastroenterol. 2001, 96, 1251–1255. DOI: 10.1111/J.1572-0241.2001.03636.X DOI: https://doi.org/10.1111/j.1572-0241.2001.03636.x
Soudah, H.C.; Hasler, W.L.; Owyang, C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N. Engl. J. Med., 1991, 325, 1461–1467. DOI: 10.1056/NEJM199111213252102 DOI: https://doi.org/10.1056/NEJM199111213252102
Cui, H.; Zhang, C.; Li, C.; Lin, L. Antibacterial mechanism of oregano essential oil. Ind. Crops Prod., 2019, 139, Art. No: 111498. DOI: 10.1016/J.INDCROP.2019.111498 DOI: https://doi.org/10.1016/j.indcrop.2019.111498
Athamneh, K.; Alneyadi, A.; Alsamri, H.; Alrashedi, A.; Palakott, A.; et al. Origanum majorana Essential Oil Triggers p38 MAPK-Mediated Protective Autophagy, Apoptosis, and Caspase-Dependent Cleavage of P70S6K in Colorectal Cancer Cells. Biomolecules 2020, 10(3), Art. No: 412. DOI: 10.3390/BIOM10030412 DOI: https://doi.org/10.3390/biom10030412
Chedid, V.; Dhalla, S.; Clarke, J.O.; Roland, B.C.; Dunbar, K.B.; et al. Herbal Therapy Is Equivalent to Rifaximin for the Treatment of Small Intestinal Bacterial Overgrowth. Glob. Adv. Health Med. 2014, 3, 16-24. DOI: 10.7453/GAHMJ.2014.019 DOI: https://doi.org/10.7453/gahmj.2014.019
Szopa, A.; Pajor, J.; Klin, P.; Rzepiela, A.; Elansary, H.O.; et al. Artemisia absinthium L.—Importance in the History of Medicine, the Latest Advances in Phytochemistry and Therapeutical, Cosmetological and Culinary Uses. Plants 2020, 9, Art. No: 1063. DOI: 10.3390/PLANTS9091063 DOI: https://doi.org/10.3390/plants9091063
Al-Snafi, A.E. The pharmacology of Equisetum arvense - A review. IOSR Journal Of Pharmacy Www.Iosrphr.Org. 2017, 7, 31–42. www.iosrphr.org (Accessed 19 Jan 2024) DOI: https://doi.org/10.9790/3013-0702013142
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Mateusz Sobczyk, Mikołaj Porzak, Daria Żuraw, Alicja Sodolska, Paulina Oleksa, Kacper Jasiński
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
